Semaglutide and tirzepatide have produced some of the largest weight reductions ever recorded in clinical trials, with losses reaching 15 percent or more of body weight and, in one landmark study, a measurable drop in heart attacks and strokes. Yet the same trials that generated those results also exposed a set of clinical unknowns that physicians are still working to resolve: what happens when patients stop the drugs, how to manage gastrointestinal side effects that drive real-world dropouts, and whether the controlled conditions of a 68- or 72-week study translate into lasting benefits for the millions of people now seeking prescriptions.
Why trial gains may not survive contact with everyday practice
The tension at the center of the weight-loss drug story is straightforward. Randomized trials delivered striking numbers under tightly managed conditions, but clinicians have limited evidence to guide what comes after. The STEP 1 investigation randomized 1,961 adults without diabetes to semaglutide 2.4 mg weekly or placebo, combined with lifestyle counseling, over 68 weeks. The drug arm lost substantially more weight than the placebo group, and responder analyses showed high proportions crossing the 5, 10, and 15 percent loss thresholds. Gastrointestinal side effects, chiefly nausea and diarrhea, were the most common adverse events and a leading reason for discontinuation even inside the trial’s structured support system.
That discontinuation problem grows sharper outside a clinical trial. The National Institute of Diabetes and Digestive and Kidney Diseases has stated explicitly that there is limited long-term safety and effectiveness research for extended use of these medications, and that it is unclear how long patients may need to stay on therapy. If cost barriers, insurance denials, or persistent nausea push patients off the drugs at higher rates than seen in trials, the downstream benefits, including cardiovascular risk reduction, will shrink accordingly. The hypothesis that real-world dropout could blunt the heart-disease gains observed in the SELECT trial by a large margin within a few years is not speculative; it follows directly from what the withdrawal data already show.
SELECT, SURMOUNT, and the hard numbers behind the headline
Three trial programs anchor the clinical case for these drugs. STEP 1 established semaglutide 2.4 mg as a potent weight-loss agent in adults with overweight or obesity but without diabetes. The SURMOUNT‑1 program then tested tirzepatide, a dual GIP/GLP-1 receptor agonist, across multiple dose arms versus placebo over 72 weeks and reported even greater weight reductions. Both trials enrolled carefully selected populations, provided regular counseling, and used slow titration schedules designed to minimize side effects.
The cardiovascular payoff came from SELECT, which tested semaglutide 2.4 mg against placebo in adults who were overweight or obese and had established cardiovascular disease but not diabetes. The trial reported a reduction in major adverse cardiovascular events, a finding that moved the drugs from a weight-management tool into a potential cardioprotective therapy. That distinction matters for insurance coverage decisions and clinical guidelines alike, because it reframes the medications as disease-modifying agents rather than purely cosmetic treatments.
Yet the SURMOUNT‑4 withdrawal study delivered a sobering counterpoint. After an initial run-in period on tirzepatide, participants were randomized either to continue therapy or switch to placebo. Those who stopped regained a substantial portion of the weight they had lost. The design confirmed what many clinicians suspected: these drugs work as long as patients take them, and stopping triggers rapid reversal. That finding reframes the entire value proposition. A 72-week trial result is meaningful only if patients can maintain therapy for years, possibly indefinitely.
For payers and policymakers, the implication is that headline efficacy numbers must be interpreted through the lens of adherence. If long-term continuation rates in routine practice fall well below those in SELECT or SURMOUNT, the average patient will experience more modest weight loss and a smaller reduction in cardiovascular events than the trials suggest. That does not negate the benefits, but it does argue for cautious modeling of population-level impact and for investment in adherence support, from side-effect management to insurance navigation.
Safety signals, compounding risks, and surgical complications
Beyond efficacy questions, regulators have flagged concrete safety concerns tied to how these drugs are used outside controlled settings. The FDA issued an alert about dosing errors with compounded injectable semaglutide, citing cases where patients or providers miscalculated doses when drawing from multi-dose vials rather than using branded auto-injector pens. Separately, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, a move that would restrict large-scale compounding of these drugs and limit the supply of cheaper alternatives that many patients have turned to during branded-product shortages.
Surgical teams have raised a parallel concern. GLP-1 receptor agonists slow gastric emptying, which increases the risk of aspiration during anesthesia. A multisociety clinical practice guidance document published in Surgery for Obesity and Related Diseases addressed the perioperative period, offering risk stratification based on dose, duration of therapy, and the presence of gastrointestinal symptoms. The authors recommended that anesthesia teams specifically ask about GLP-1 use, consider holding weekly injections for a period before elective surgery in higher-risk patients, and adjust fasting protocols or use gastric ultrasound when uncertainty remains. For urgent procedures, they advised treating patients as having a “full stomach” and using airway-protective techniques.
These recommendations underscore a broader theme: as GLP-1 and GIP/GLP-1 agonists diffuse into primary care and even med-spa settings, coordination with other specialties becomes essential. Endocrinologists and obesity-medicine physicians may be familiar with the nuances of dose escalation and gastrointestinal side effects, but surgeons, anesthesiologists, and emergency physicians increasingly encounter patients on these drugs without that context. Clear communication about timing of the last dose, current symptoms, and prior episodes of severe nausea or vomiting can reduce avoidable perioperative risks.
Balancing enthusiasm with uncertainty
The clinical community now faces a dual responsibility. On one hand, semaglutide and tirzepatide represent a genuine advance for people with obesity and obesity-related cardiovascular disease, offering levels of weight loss and event reduction that lifestyle counseling alone rarely achieves. On the other hand, the same evidence base that justifies their use also highlights unresolved questions about duration of therapy, long-term safety, and how to manage treatment interruptions driven by side effects, pregnancy, or cost.
For individual patients, realistic counseling may be the most important immediate step. Physicians can present GLP-1–based drugs not as a short-term fix, but as part of a chronic-disease strategy that likely involves years of therapy, ongoing attention to diet and physical activity, and periodic reassessment of cardiovascular risk. They can also emphasize the possibility of weight regain after stopping and discuss in advance how to respond if supply shortages or insurance changes force a temporary pause.
At the system level, the next phase of research will need to move beyond 72-week efficacy trials toward pragmatic studies that track adherence, discontinuation, and cardiovascular outcomes in routine care. Registries that capture reasons for stopping, patterns of weight regain, and the incidence of rare adverse events could help refine risk–benefit calculations. Meanwhile, regulators and professional societies will continue to adjust guidance on compounding, perioperative management, and monitoring for known and emerging side effects.
In the end, the story of semaglutide and tirzepatide is not just about dramatic before-and-after photos or record-breaking trial results. It is about whether health systems can translate those numbers into durable, equitable improvements in cardiometabolic health while acknowledging that, for many patients, the hardest part begins after the clinical trial ends.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
